This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
14 Feb 2020

FDA success for MedPharm Centre of Excellence

The inspection was triggered by data generated by MedPharm as part of a client’s ANDA for a generic topical product.

MedPharm, a global contract development organization for topical and transdermal products, has successfully completed a pre-approval inspection by the FDA at its facility in Durham, NC.

The FDA inspectors found the site to be compliant and no Form 483 observations issued.

The inspection, which took place 27-31 January, was triggered by data generated by MedPharm as part of a client’s ANDA for a generic topical product. The ANDA submission used MedPharm’s in vitro models to demonstrate the bioequivalence of the new generic to the originator in line with the new FDA guidelines. The inspection coincides with the recent expansion of the Durham facilities to triple its Center of Excellence footprint and accommodate up to 100 employees in the future.

"This successful outcome of the inspection by the FDA is a direct reflection of the innovation and quality inherent in everything MedPharm does and a strong endorsement of the integrity and diligence of our scientific team," commented Eugene Ciolfi, MedPharm’s President and CEO. "I would like to congratulate the Durham team as well as the entire MedPharm global group. This underlines the quality of the sophisticated and proprietary in vitro models MedPharm has developed to de-risk clients’ development programs."

Related News